By Sabela Ojea
Hims & Hers is expanding its weight-loss offering on its telehealth platform with the addition of Eli Lilly's Zepbound prescription and generic liraglutide.
The stock was up 7% to $31.62 in afternoon trading. Shares have risen around 31% year to date.
The telehealth-consultation platform on Tuesday said its aim is to bring customers more treatment options that best suit their needs.
"We've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform," the company said.
Hims & Hers' platform already offers weight-loss brands including Novo Nordisk's Ozempic and Wegovy.
Hims & Hers plans to continue expanding its weight loss offering to deliver a more personalized experience to its customer base, the company added.
"All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond," Hims & Hers said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 01, 2025 15:02 ET (19:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。